Merck Animal Health	
Financial Details	
Total Company Revenue in 2010	\$ 46 Bn
Revenue from Animal Health Market in 2010	\$ 2.9 Bn
% of revenue from Animal Health in 2010	6.30%
Segmentwise Revenue Breakup (\$ Bn)	
Livestock Vaccines	2.233
Companion Vaccines	0.667
Number of Major Vaccines (Animal-wise)	
Poultry	3
Swine	1
Fish	1
Sheep	1
Cattle	3
Canine	1
Feline	1
Equine	2
Mergers and Acquisitions (2009 - 2011)	Consideration
Schering-Plough	\$ 41 Bn
Future Focus Areas	
Veterinary Vaccines under trial	0
	Viral and parasitological vaccines
Future Focus Areas of the company in the Veterinary Vaccines Market	In pharmaceutical R&D, Merck has 120 ongoing projects focusing on parasiticides, anti-infectives and internal medicine (endocrine/pain) and performance products.
	In biological R&D, Merck has 140 projects in progress focusing on zoonotic and emerging diseases, respiratory diseases, enteric diseases and enabling technologies.